In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Schering AG licenses 3-Dimensional's urokinase inhibitors

Executive Summary

Schering AG licensed exclusive worldwide rights for human therapeutic uses to 3-Dimensional's urokinase inhibitors, paying (uf)$5mm up front through an equity purchase of 625k Series D preferred shares, $5mm in R&D funds, and up to $23mm in milestones for the first product that makes it to market. It will also pay royalties on net sales.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies